We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

112 hedge funds and large institutions have $370M invested in BioCryst Pharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 37 increasing their positions, 28 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

214% more call options, than puts

Call options by funds: $25.2M | Put options by funds: $8.02M

111% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 9

79.16% more ownership

Funds ownership: 0% → 79.16% (+79%)

49% more capital invested

Capital invested by funds: $248M → $370M (+$122M)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

32% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 28

9% more funds holding

Funds holding: 103 → 112 (+9)

Holders
112
Holders Change
+9
Holders Change %
+8.74%
% of All Funds
2.8%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.1%
New
19
Increased
37
Reduced
28
Closed
9
Calls
$25.2M
Puts
$8.02M
Net Calls
+$17.1M
Net Calls Change
+$17.5M

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$6.92M
2
State Street
State Street
Massachusetts
+$3.87M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$2.59M
4
BFA
BlackRock Fund Advisors
California
+$1.95M
5
VMI
VHCP Management II
New York
+$1.82M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$6.06M
2
GTC
Ghost Tree Capital
New York
-$3.38M
3
ACP
Acuta Capital Partners
California
-$2.1M
4
PC
Paulson & Co
New York
-$1.62M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$1.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
BIM
26
BlackRock Investment Management
Delaware
$1.86M -$7.56K -1,453 -0.5%
Charles Schwab
27
Charles Schwab
California
$1.71M +$69.7K +13,398 +5%
Millennium Management
28
Millennium Management
New York
$1.18M +$655K +125,838 +206%
California State Teachers Retirement System (CalSTRS)
29
California State Teachers Retirement System (CalSTRS)
California
$957K -$22.4K -4,300 -3%
ACP
30
Acuta Capital Partners
California
$950K -$2.1M -404,448 -73%
RA
31
Royce & Associates
New York
$912K -$83.3K -16,000 -10%
PP
32
PDT Partners
New York
$828K -$162K -31,106 -19%
TA
33
Teachers Advisors
New York
$796K +$102K +19,615 +18%
California Public Employees Retirement System
34
California Public Employees Retirement System
California
$781K – – –
AllianceBernstein
35
AllianceBernstein
Tennessee
$761K -$31.2K -6,000 -5%
Wells Fargo
36
Wells Fargo
California
$750K +$469K +90,103 +318%
Citadel Advisors
37
Citadel Advisors
Florida
$702K +$577K +110,854 New
UBS Group
38
UBS Group
Switzerland
$632K +$60.1K +11,547 +13%
Swiss National Bank
39
Swiss National Bank
Switzerland
$610K – – –
RhumbLine Advisers
40
RhumbLine Advisers
Massachusetts
$536K +$17.8K +3,418 +4%
Federated Hermes
41
Federated Hermes
Pennsylvania
$531K +$15.5K +2,983 +4%
Group One Trading
42
Group One Trading
Illinois
$514K +$403K +77,460 +2,084%
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
$439K – – –
DCM
44
DAFNA Capital Management
California
$417K +$343K +65,900 New
CS
45
Credit Suisse
Switzerland
$409K -$243K -46,772 -42%
Barclays
46
Barclays
United Kingdom
$396K +$318K +61,050 +4,318%
ProShare Advisors
47
ProShare Advisors
Maryland
$383K +$35.3K +6,790 +13%
MLICM
48
Metropolitan Life Insurance Company (MetLife)
New York
$359K -$22.9K -4,399 -7%
State Board of Administration of Florida Retirement System
49
State Board of Administration of Florida Retirement System
Florida
$345K – – –
PC
50
Paulson & Co
New York
$333K -$1.62M -310,500 -86%
1
2
3 4 5

BCRX Hedge Fund Activity: Q4 2016 in Review

112 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q4 2016, worth a combined $370M — up 49% from $248M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new BCRX positions and 9 closed out — a net gain of 10 holders — while 37 added to existing stakes and 28 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $6.92M. The largest seller was Deerfield Management, cutting an estimated $6.06M.

  • 112 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q4 2016, up from 103 in Q3 2016.
  • Funds reported $370M of BioCryst Pharmaceuticals stock for Q4 2016, up 49% quarter-over-quarter.
  • 19 funds opened new BioCryst Pharmaceuticals positions in Q4 2016 and 9 closed out, a net change of +10 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q4 2016 was Perceptive Advisors, an estimated $6.92M added.
  • The largest BioCryst Pharmaceuticals seller in Q4 2016 was Deerfield Management, an estimated $6.06M sold.

Based on aggregated 13F filings for Q4 2016.